Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMAMNASDAQ:MOLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMAMAmbrx Biopharma$28.00$27.94$6.55▼$28.15$1.77B-1.922.12 million shsN/AMOLNMolecular Partners$4.42-1.8%$5.08$3.32▼$12.70$178.40M1.064,584 shs4,299 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMAMAmbrx Biopharma0.00%0.00%0.00%0.00%0.00%MOLNMolecular Partners-4.23%-9.80%-12.89%-20.36%+10.78%Remove AdsMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMAMAmbrx BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AMOLNMolecular Partners2.9673 of 5 stars3.85.00.00.02.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMAMAmbrx Biopharma 0.00N/AN/AN/AMOLNMolecular Partners 3.50Strong Buy$12.00171.49% UpsideCurrent Analyst Ratings BreakdownLatest AMAM and MOLN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/11/2025MOLNMolecular PartnersLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.00(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMAMAmbrx Biopharma$7.40M238.95N/AN/A$3.05 per share9.18MOLNMolecular Partners$4.97M35.90N/AN/A$5.41 per share0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMAMAmbrx Biopharma-$78MN/A0.00N/AN/AN/AN/AN/AN/AMOLNMolecular Partners-$69.04M-$1.81N/AN/AN/A-1,043.01%-39.31%-35.46%4/17/2025 (Estimated)Latest AMAM and MOLN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/6/2025Q4 2024MOLNMolecular Partners-$0.45-$0.34+$0.11-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMAMAmbrx BiopharmaN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMAMAmbrx BiopharmaN/A13.2813.28MOLNMolecular PartnersN/A14.3314.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMAMAmbrx Biopharma77.28%MOLNMolecular Partners26.55%Insider OwnershipCompanyInsider OwnershipAMAMAmbrx Biopharma0.64%MOLNMolecular Partners5.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMAMAmbrx Biopharma8763.15 million62.75 millionOptionableMOLNMolecular Partners18040.36 million37.97 millionNot OptionableAMAM and MOLN HeadlinesRecent News About These CompaniesMolecular Partners (NASDAQ:MOLN) Coverage Initiated by Analysts at Lifesci CapitalMarch 12 at 8:58 AM | marketbeat.comLifeSci Capital Initiates Coverage of Molecular Partners AG - Depositary Receipt () (MOLN) with Outperform RecommendationMarch 12 at 6:43 AM | msn.comMolecular Partners initiated with an Outperform at LifeSci CapitalMarch 11 at 10:18 PM | markets.businessinsider.comLeerink Partnrs Weighs in on MOLN FY2024 EarningsMarch 11 at 1:21 AM | americanbankingnews.comMolecular Partners AG (NASDAQ:MOLN) Q4 2024 Earnings Call TranscriptMarch 10 at 12:40 PM | msn.comFY2024 Earnings Estimate for MOLN Issued By Leerink PartnrsMarch 10 at 1:16 AM | marketbeat.comMolecular Partners Full Year 2024 Earnings: CHF1.59 loss per share (vs CHF1.89 loss in FY 2023)March 9, 2025 | finance.yahoo.comMolecular Partners AG (MLLCF) (FY 2024) Earnings Call Highlights: Strategic Shifts and ...March 8, 2025 | gurufocus.comFull Year 2024 Molecular Partners AG Earnings Call TranscriptMarch 8, 2025 | gurufocus.comMolecular Partners AG: Strategic Advances and Financial OverviewMarch 7, 2025 | tipranks.comMolecular Partners (NASDAQ:MOLN) Releases Earnings Results, Beats Estimates By $0.11 EPSMarch 7, 2025 | marketbeat.comMolecular Partners AG (MOLN) Q4 2024 Earnings Call TranscriptMarch 7, 2025 | seekingalpha.comMolecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024March 6, 2025 | globenewswire.comMolecular Partners (MOLN) Projected to Post Earnings on ThursdayMarch 5, 2025 | americanbankingnews.comMolecular Partners (NASDAQ:MOLN) Trading 0.3% Higher - What's Next?March 1, 2025 | marketbeat.comMolecular Partners (MOLN) Expected to Announce Quarterly Earnings on ThursdayMarch 1, 2025 | marketbeat.comMolecular Partners AG to Present at TD Cowen and Leerink Healthcare Conferences; Conference Call Scheduled for March 7 on 2024 Financial ResultsFebruary 28, 2025 | quiverquant.comMolecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference CallFebruary 28, 2025 | globenewswire.comInvestors in Molecular Partners (VTX:MOLN) have unfortunately lost 81% over the last three yearsJanuary 28, 2025 | finance.yahoo.com(MOLN) Trading AdviceJanuary 22, 2025 | news.stocktradersdaily.comMolecular Partners AG Announces Key Developments in Radio-DARPin Programs and Expansion of Partnership with Orano MedJanuary 12, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMAM and MOLN Company DescriptionsAmbrx Biopharma NYSE:AMAMAmbrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.Molecular Partners NASDAQ:MOLN$4.42 -0.08 (-1.78%) Closing price 03/12/2025 03:59 PM EasternExtended Trading$4.32 -0.11 (-2.38%) As of 03/12/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
